innoscripta (1INN.MU) Stock Price

innoscripta Price

CLOSED
44.15
​
Market closed

Revenue has compounded at 56.0% per year over the past 3 years to 103.37 M EUR. Earnings per share have grown at 91.2% per year over the last 3 years. innoscripta's net margin stands at 41.2%, up from 22.4% several years earlier.

innoscripta stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

innoscripta business model & stock analysis

innoscripta SE generates revenue through its SaaS platform providing cloud-based compliance software for R&D tax credits and project management. The company serves funding consulting and support companies across various industries, offering tools for project management, time recording, employee management, and data interfaces to third-party systems. Its platform helps clients identify, validate, and manage R&D projects while ensuring compliant documentation for tax credits. The firm's SaaS solution is designed to streamline R&D process management for clients in diverse sectors. innoscripta SE's primary customers are funding consulting and support companies that assist businesses in securing R&D funding. These clients use the company's software to manage documentation, track project progress, and interface with external systems. The platform's focus on compliance and tax credit validation makes it essential for clients navigating complex regulatory environments. The company's revenue model relies on subscription-based access to its integrated software suite. The business model centers on delivering a comprehensive SaaS solution that integrates multiple functions into one platform. By combining project management, time tracking, employee management, and third-party data integration, innoscripta SE provides a unified system for R&D project oversight. This approach reduces the need for multiple software tools, appealing to clients seeking efficiency and compliance in their R&D operations.

Frequently asked questions about innoscripta

8 analysts currently rate the innoscripta stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect innoscripta to generate revenue of 149.10 M EUR and earnings per share of 24.29 EUR.

The expected revenue of innoscripta is 149.10 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of innoscripta is 242.90 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of innoscripta is currently 1.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the innoscripta stock.

The price-to-sales ratio (P/S) of innoscripta is currently 2.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the innoscripta stock.

The Eulerpool Quality Score for innoscripta is 7/10.

The ISIN of innoscripta is DE000A40QVM8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of innoscripta is 1INN.MU. The ticker symbol is used to trade innoscripta shares on the stock exchange.

Fair ValueTerminal
41.94 EUR
Over-/UndervaluationTerminal
Fairly valued
Industry
Software
Number of shares
Employees
Revenue per Employee
313,236.52 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
EUR
Initial public offering
May 21, 2025
ISIN
DE000A40QVM8
Cusip
D3687G104
Market capitalization
441.50 M EURSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
1.82
P/Ee 2027
1.39
P/S
P/Se
2.96
EV/EBIT
6.38
P/B Ratio
8.21
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
66.29 %
Last updated Nov 9, 2026, 3:41 AM

innoscripta Peer Group

All fundamentals and in-depth analysis of innoscripta

Our stock analysis for innoscripta stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of innoscripta. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.